NeurAxis, Inc. (NRXS) Q4 2024 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reflects a positive sentiment with strong revenue growth, improved margins, and reduced losses. The introduction of the Category 1 CPT code and insurance coverage expansion are significant catalysts. Despite some uncertainties in product development timelines, the overall outlook is optimistic with expectations of increased margins and breakeven targets. The Q&A session reinforces this positivity, highlighting strong market feedback and minimal risk exposure. Given these factors, the stock is likely to experience a positive movement in the coming weeks.
Key Financial Performance
Revenue Q4 2024 $761,000, up 43% from $531,000 in Q4 2023 due to increased unit sales from undiscounted insurance reimbursement and financial assistance programs.
Revenue FY 2024 $2.7 million, an increase of 9% compared to $2.5 million in FY 2023, driven by a 19% increase in unit sales from financial assistance programs.
Gross Margin Q4 2024 86.4%, unchanged from Q4 2023, despite an increase in discounted financial assistance units.
Gross Margin FY 2024 86.5%, down from 87.7% in FY 2023, due to growth in discounted device deliveries.
SG&A Expenses Q4 2024 $2.1 million, up 2% from $2 million in Q4 2023, due to hiring and a short-term incentive plan.
SG&A Expenses FY 2024 $9.5 million, up 7% from $8.8 million in FY 2023, due to increased headcount and one-time costs.
Operating Loss Q4 2024 $1.5 million, improved by 10% from $1.6 million in Q4 2023, due to higher sales volumes.
Operating Loss FY 2024 $7.2 million, an increase of 7% from $6.7 million in FY 2023, due to higher SG&A costs.
Net Loss Q4 2024 $1.5 million, a decrease of 73% from $5.3 million in Q4 2023, primarily due to a lower operating loss.
Net Loss FY 2024 $8.2 million, a decrease of 45% from $14.6 million in FY 2023, due to the absence of debt extinguishment charges.
Cash on Hand $3.7 million as of December 31, 2024, with no long-term debt.
Cash Used in Operations FY 2024 $6.1 million, $595,000 lower than FY 2023, due to more stock issuance for services and lower interest payments.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
IB-Stim: Continuing commercialization of IB-Stim technology for IBS, with significant growth of 43% in Q4 2024.
RED: FDA clearance received for RED, a rectal expulsion device, allowing for a soft launch.
Market Expansion: Expansion of IB-Stim age indication from 11-18 years to 8-21 years, nearly doubling market opportunity.
Covered Lives: Increase in covered lives from 4 million to approximately 51 million.
Operational Efficiency: Achieved a Category 1 CPT code effective January 1, 2026, facilitating easier billing and reimbursement.
Revenue Growth: Revenue in Q4 2024 was $761,000, up 43% year-over-year.
Strategic Shift: Focus on obtaining national insurance coverage and effective CPT code to drive revenue growth.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Insurance Coverage Risks: The company faces challenges in obtaining written insurance policy coverage on a national level, which is critical for revenue growth. The lack of coverage has hindered the adoption of their technology in children's hospitals.
Regulatory Risks: The effective date for the Category 1 CPT code is January 1, 2026, which is crucial for billing and reimbursement. Delays or changes in regulatory approvals could impact revenue.
Market Adoption Risks: Despite significant growth in covered lives, the company is still treating a small percentage of the addressable market due to insurance barriers. This limits potential revenue.
Economic Factors: The company relies on insurance reimbursement for revenue, and any economic downturns affecting healthcare spending could impact their financial performance.
Operational Risks: The transition from discounted financial assistance to full reimbursement is expected to take time, which may delay revenue realization.
Competition Risks: The competitive landscape in the healthcare technology sector may pose challenges as other companies may offer similar or superior solutions.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Commercialization Strategy: Continuing accomplishments in commercialization strategies for IB-Stim and RED, with significant growth in covered lives and new FDA indications.
Market Expansion: IB-Stim age expansion from 11-18 years to 8-21 years, nearly doubling market opportunity.
Insurance Coverage: Increased covered lives from 4 million to approximately 51 million, with ongoing efforts to secure additional payers.
Category 1 CPT Code: Achieved a permanent Category 1 CPT code effective January 1, 2026, facilitating easier billing and reimbursement.
FDA Milestones: Received FDA clearance for RED, a device for pelvic floor dysfunction, and submitted for expanded indication for functional dyspepsia.
Revenue Growth: Expect significant revenue growth as national insurance coverage and Category 1 CPT code take effect.
Financial Projections: Revenue in Q4 2024 was $761,000, up 43% YoY; FY 2024 revenue was $2.7 million, up 9% YoY.
Gross Margin: Maintained gross margin of 86.4% in Q4 2024, with expectations for improvement post-2026.
Cash Flow Breakeven: Goal to reach cash flow breakeven based on sales volume and insurance coverage expansion.
Operational Outlook: Anticipate continued revenue growth in Q1 2025, marking the third consecutive quarter of growth.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Category 1 CPT Code: A permanent billing code effective January 1, 2026, facilitating easier revenue cycle management and reimbursement.
Insurance Coverage: Increased from 4 million covered lives to approximately 51 million covered lives, indicating significant growth in insurance policy coverage.
Financial Assistance Program: Provides discounts to patients without insurance, impacting revenue but expected to transition to full reimbursement with the Category 1 CPT code.
Revenue Growth: Fourth quarter 2024 revenue was $761,000, up 43% from $531,000 in Q4 2023, with unit sales increasing approximately 45%.
Gross Margin: Maintained at 86.4% in Q4 2024, with expectations of improvement as the Category 1 CPT code takes effect.
Operating Loss: Reduced to $1.5 million in Q4 2024, a 10% improvement compared to Q4 2023.
Net Loss: Decreased to $1.5 million in Q4 2024, down 73% from $5.3 million in Q4 2023.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you talk about the significance of receiving the Category 1 code and the 510(k) extensions?
A:The Category 1 code is significant as it allows physicians to receive RVUs for procedures, which is crucial for their compensation. It streamlines prior authorizations and adds credibility with payers. The 510(k) extension increases the addressable market by expanding the age range for treatment from 11-18 to 8-21.
Q:Can you talk about the variability of the gross margins and how to think about gross margins on a go-forward basis?
A:Reported gross margins are in the mid to high 80s. Higher margins are seen when selling to insured patients, but financial assistance programs lower overall margins. Future gross margins are expected to increase as more patients gain insurance coverage due to the Category 1 code.
Q:What are some of the early learnings from the RED in the commercial mode that you are in now?
A:Feedback has been positive, with higher than expected usage from physicians. The commercial force is excited, and they anticipate meaningful revenues in Q2.
Q:Given the expected cost structure, what level of revenue do you need to achieve breakeven?
A:Breakeven revenues will be in the $10 million to $12 million range, given the current cash burn rate of $6 million annually.
Q:Where are your products manufactured and what is your exposure to any potential tariffs?
A:95% of technology is sourced and manufactured in the U.S., with minimal exposure to tariffs.
Q:What is the development time-line for a second-generation IB-Stim device and how will that differ from the current version?
A:Generation 2 is expected in 2026, with a modern look and potential features to indicate functionality. Research and development are ongoing.
Q:What is the response after a three-week or four-week course of IB-Stim treatment and what percentage of patients come back for additional treatment courses?
A:About 70% of patients report significant long-term relief after treatment, with results being sustainable. Multiple studies support this data.
Q:Review of Unclear Management Responses
A:Management avoided giving a direct answer regarding the exact percentage of increased revenue from the age expansion and the specifics of the second-generation device features, indicating that they are still in the research phase.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Academic Society
Code
ET day
FDA indication
IPO loss
NASPGHAN
Officer Conference
RVUs
SGA increase
Society guideline
Unit sale
age market
age year
assistance program
charge
clearance technology
conference NeurAxis
coverage Category
decrease loss
disorder
dyspepsia
flow breakeven
form
goal cash
incentive plan
introduction term
loss decrease
momentum
order demand
patient insurance
procedure reimbursement
quarter
sale finance
sale patient
service
technology RED
term debt
term incentive
world
year age
NRXS Transcript
NeurAxis, Inc. (NRXS) Q3 2025 Earnings Call Transcript
Unknown11-11
The earnings call reveals mixed sentiments. Basic financial performance shows revenue growth but also increased losses and expenses. Product updates, like the RED launch, face adoption challenges, and there's uncertainty in market strategy due to reliance on the new CPT code. The Q&A highlights cautious optimism but lacks concrete details, leading to investor uncertainty. Despite positive long-term prospects, short-term hurdles and management's vague responses temper enthusiasm. Overall, the sentiment remains neutral, expecting minimal stock price movement in the short term.
NeurAxis, Inc. (NRXS) Q2 2025 Earnings Call Transcript
Positive8-12
The earnings call revealed strong revenue growth (39% in Q1 2025) and a significant increase in unit sales (58% YoY), despite a slight decline in gross margin. Operating expenses and losses decreased, showing improved cost management. The Q&A highlighted positive responses from insurance payers and potential for expanded insurance coverage, which could boost future sales. While there are uncertainties in policy writing speed and coverage timelines, the overall sentiment is positive due to revenue growth, cost management, and optimistic insurance coverage outlook.
NeurAxis, Inc. (NRXS) Q1 2025 Earnings Call Transcript
Neutral5-12
NeurAxis, Inc. (NASDAQ:NRXS) Q4 2024 Earnings Call Transcript
Positive3-22
The earnings call reflects strong financial performance, with a 25% revenue increase and improved margins, alongside positive product development updates. The Q&A highlights significant market expansion opportunities and favorable insurance coverage impacts. Concerns exist regarding regulatory risks and competitive pressures, but the company has a solid plan for growth and breakeven achievement. Overall, the sentiment is positive, indicating a likely stock price increase in the short term, despite some risks.
NRXS Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
